Starpharma BV treatment Phase 3 trial receives FDA approval
The FDA has proposed design of Phase 3 studies and the development program in support of a New Drug Application (NDA) for VivaGel to treat BV. The two
HAYA Therapeutics has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational therapy, HTX-001, to treat symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
Juvisync combines Januvia (sitagliptin), the glucose-lowering medication with the cholesterol-lowering medication Zocor (simvastatin). According to the company, Juvisync is said to provide blood sugar-lowering benefits of a DPP-4